Ninety-five patients undergoing an allogeneic bone marrow transplant (BMT) and developing acute graft-versus-host disease (aGvHD) were randomized to receive low-dose intravenous 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47) or high-dose 6MPred (10 mg/kg/d; n = 48) for 5 days, with subsequent tapering doses. On day 5 patients not responding or progressing on low-dose 6MPred could be switched to high-dose 6MPred. All patients, aged 1 to 55 years, were recipients of unmanipulated BMT from HLA identical sibling donors. Patients were stratified at randomization for age (
Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation / Van Lint, M. T.; Uderzo, C.; Locasciulli, A.; Majolino, I.; Scime, R.; Locatelli, F.; Giorgiani, G.; Arcese, W.; Iori, A. P.; Falda, M.; Locatelli, F.; Bosi, A.; Miniero, R.; Alessandrino, P.; Dini, G.; Rotoli, B.; Bacigalupo, A.. - In: BLOOD. - ISSN 0006-4971. - 92:7(1998), pp. 2288-2293.
Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation
Locatelli F.;
1998
Abstract
Ninety-five patients undergoing an allogeneic bone marrow transplant (BMT) and developing acute graft-versus-host disease (aGvHD) were randomized to receive low-dose intravenous 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47) or high-dose 6MPred (10 mg/kg/d; n = 48) for 5 days, with subsequent tapering doses. On day 5 patients not responding or progressing on low-dose 6MPred could be switched to high-dose 6MPred. All patients, aged 1 to 55 years, were recipients of unmanipulated BMT from HLA identical sibling donors. Patients were stratified at randomization for age (I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
